Markus Klinger

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

Markus Klinger, Sandra Eipeldauer, Stefan Hacker et al. · European Journal of Surgical Oncology · 2009 · 157 citations

Medicine, Oncology, Pharmacology +17

Influence of Hepatic Resection Margin on Recurrence and Survival in Intrahepatic Cholangiocarcinoma

Dietmar Tamandl, Beata Herberger, Birgit Gruenberger et al. · Annals of Surgical Oncology · 2008 · 155 citations

Medicine, Oncology, Surgery +11

Sinusoidal Obstruction Syndrome Impairs Long-Term Outcome of Colorectal Liver Metastases Treated with Resection after Neoadjuvant Chemotherapy

Dietmar Tamandl, Markus Klinger, Sandra Eipeldauer et al. · Annals of Surgical Oncology · 2010 · 133 citations

Medicine, Oncology, Surgery +14

Activation of Mitogen-activated Protein Kinase by the A2A-adenosine Receptor via a rap1-dependent and via a p21 -dependent Pathway

Markus G. Seidel, Markus Klinger, Michael Freissmuth et al. · Journal of Biological Chemistry · 1999 · 124 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX

Markus Klinger, Dietmar Tamandl, Sandra Eipeldauer et al. · Annals of Surgical Oncology · 2010 · 104 citations

Medicine, Oncology, Pharmacotherapy +14